Master data| INID | Criterion | Field | Content |
|---|
| Type of IP right | SART | Patent |
| Status | ST | Not pending/lapsed |
| 21 | DE file number | DAKZ | 60 2005 051 274.8 |
| 96 | EP file number | EAKZ | 12 15 7945.2 |
| 97 | EP publication number | EPN | 2471551 |
| 54 | Designation/title | TI | Verringerung potentieller iatrogener Risiken, die mit Influenza-Impfstoffen zusammenhängen |
| 51 | IPC main class | ICM
(ICMV) | A61K 39/145 (2006.01) |
| 51 | IPC secondary class(es) | ICS
(ICSV) | C12Q 1/70 (2006.01) |
| 22 | DE application date | DAT | Sep 9, 2005 |
| 96 | EP application date | EAT | Sep 9, 2005 |
| 43 | Date of first publication | OT | Jul 4, 2012 |
| Date of publication of grant | PET | Feb 1, 2017 |
| 71/73 | Applicant/owner | INH | Novartis AG, 4056 Basel, CH |
| 72 | Inventor | IN | Gregersen, Jens Peter, 35041 Marburg, DE |
| Address for service | | Novartis AG, 4056 BASEL, CH |
33
31
32
| Foreign priority | PRC
PRNA
PRDA
| EP
04255471
Sep 9, 2004
|
| Patent division in charge | | 44 |
| 97 | EP language of publication | ELANG | EN - Englisch |
| 84 | Designated EP contracting states | EDS | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000002471551
Searchable text:
EP000002471551
Original document:
EP000002471551B1
Searchable text:
EP000002471551B1 |
| 43 | Date of first publication | EVT | Jul 4, 2012 |
| Date of the first transfer into DPMAregister | EREGT | Aug 17, 2012 |
| Date of the (most recent) update in DPMAregister | REGT | Jan 7, 2024
(Show all update days)(Hide all update days)- Jan 7, 2024; Aug 19, 2019; Jul 11, 2019; Jun 28, 2018; May 22, 2018; Jan 16, 2018; Dec 28, 2017; Oct 11, 2017; Mar 16, 2017; Feb 7, 2017; Feb 2, 2017; Sep 15, 2016; Apr 17, 2013; Mar 30, 2013; Feb 13, 2013; Jan 30, 2013; Dec 20, 2012
- Historical data not available for this/these date(s)
- Aug 17, 2012
- Date of the first transfer into DPMAregister
|
